European Association of Urology has selected Dicot's study result to be presented
Uppsala, December 21, 2021. The pharmaceutical company Dicot announces that the results showing effect of Dicot's drug candidate in a disease animal model will be presented at the European Association of Urology's (EAU) annual congress 2022 in Amsterdam.
The European Association of Urology (EAU) has announced that study results from Dicot's drug candidate will be presented at the EAU's annual congress in Amsterdam in March 2022. Thousands of abstracts from scientists are submitted to EAU. EAU annual congress is the central platform for successful research and innovation.
The results to be presented at EAU is from the study that demonstrated the effect of Dicot's drug candidate in animals with diabetes and proven erectile dysfunction. About 70% of patients who have diabetes and suffer from erectile dysfunction do not respond well to current treatments.
"The fact that our study results are selected to be presented at EAU's annual congress validates how exceptional our results are in this scientific area, which is very gratifying.", says Göran Beijer, CEO of Dicot.
Dicot previously announced that the European Society for Sexual Medicine, the leading scientific organization in sexual medicine, has selected an abstract from Dicot to be presented at the ESSM's annual congress in Rotterdam in February 2022.
For more information, please contact:
Göran Beijer CEO
Phone: +46 706 63 60 09
Email: [email protected]
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.
Om Dicot
Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.
Handelsinformation
IR-Kontakt
